Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

Fumiyo Nakagawa; Rebecca Lodwick; Dominique Costagliola; Ard van Sighem; Carlo Torti; Daniel Podzamczer; Amanda Mocroft; Bruno Ledergerber; Maria Dorrucci; Alessandra Cozzi-Lepri; Klaus Jansen; Bernard Masquelier; Federico García; Stephane De Wit; Christoph Stephan; Niels Obel; Gerd Fätkenhaeuer; Antonella Castagna; Helen Sambatakou; Cristina Mussini; Jade Ghosn; Robert Zangerle; Xavier Duval; Laurence Meyer; Santiago Perez-Hoyos; Céline Fabre Colin; Jesper Kjaer; Genevieve Chene; Jesper Grarup; Andrew Phillips; Pursuing Later Treatment Options II (PLATO II) project team

doi:10.1097/qai.0b013e31823fe66b

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

Fumiyo Nakagawa, Rebecca Lodwick, Dominique Costagliola, Ard van Sighem, Carlo Torti, Daniel Podzamczer, Amanda Mocroft, Bruno Ledergerber, Maria Dorrucci, Alessandra Cozzi-Lepri, Klaus Jansen, Bernard Masquelier, Federico García, Stephane De Wit, Christoph Stephan, Niels Obel, Gerd Fätkenhaeuer, Antonella Castagna, Helen Sambatakou, Cristina MussiniJade Ghosn, Robert Zangerle, Xavier Duval, Laurence Meyer, Santiago Perez-Hoyos, Céline Fabre Colin, Jesper Kjaer, Genevieve Chene, Jesper Grarup, Andrew Phillips, Pursuing Later Treatment Options II (PLATO II) project team

13 Citationer (Scopus)

Abstract

Background: Despite the increasing success of antiretroviral therapy (ART), virologic failure of the 3 original classes [tripleclass virologic failure, (TCVF)] still develops in a small minority of patients who started therapy in the triple combination ART era. Trends in the incidence and prevalence of TCVF over calendar time have not been fully characterised in recent years. Methods: Calendar time trends in the incidence and prevalence of TCVF from 2000 to 2009 were assessed in patients who started ART from January 1, 1998, and were followed within the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Results: Of 91,764 patients followed for a median (interquartile range) of 4.1 (2.0-7.1) years, 2722 (3.0%) developed TCVF. The incidence of TCVF increased from 3.9 per 1000 person-years of follow- up [95% confidence interval (CI): 3.7 to 4.1] in 2000 to 8.8 per 1000 person-years of follow-up (95% CI: 8.5 to 9.0) in 2005, but then declined to 5.8 per 1000 person-years of follow-up (95% CI: 5.6 to 6.1) by 2009. The prevalence of TCVF was 0.3% (95% CI: 0.27% to 0.42%) at December 31, 2000, and then increased to 2.4% (95% CI: 2.24% to 2.50%) by the end of 2005. However, since 2005, TCVF prevalence seems to have stabilized and has remained below 3%. Conclusions: The prevalence of TCVF in people who started ART after 1998 has stabilized since around 2005, which most likely results from the decline in incidence of TCVF from this date. The introduction of improved regimens and better overall HIV care is likely to have contributed to these trends. Despite this progress, calendar trends should continue to be monitored in the long term.

Originalsprog	Engelsk
Tidsskrift	J A I D S
Vol/bind	59
Udgave nummer	3
Sider (fra-til)	294-9
Antal sider	6
ISSN	1525-4135
DOI	https://doi.org/10.1097/qai.0b013e31823fe66b
Status	Udgivet - 1 mar. 2012

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1097/qai.0b013e31823fe66b

Andre filer og links

http://www.ncbi.nlm.nih.gov/pubmed/22083070

Citationsformater

Nakagawa, F., Lodwick, R., Costagliola, D., van Sighem, A., Torti, C., Podzamczer, D., Mocroft, A., Ledergerber, B., Dorrucci, M., Cozzi-Lepri, A., Jansen, K., Masquelier, B., García, F., De Wit, S., Stephan, C., Obel, N., Fätkenhaeuer, G., Castagna, A., Sambatakou, H., ... Pursuing Later Treatment Options II (PLATO II) project team (2012). Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. J A I D S, 59(3), 294-9. https://doi.org/10.1097/qai.0b013e31823fe66b

Nakagawa, F, Lodwick, R, Costagliola, D, van Sighem, A, Torti, C, Podzamczer, D, Mocroft, A, Ledergerber, B, Dorrucci, M, Cozzi-Lepri, A, Jansen, K, Masquelier, B, García, F, De Wit, S, Stephan, C, Obel, N, Fätkenhaeuer, G, Castagna, A, Sambatakou, H, Mussini, C, Ghosn, J, Zangerle, R, Duval, X, Meyer, L, Perez-Hoyos, S, Fabre Colin, C, Kjaer, J, Chene, G, Grarup, J, Phillips, A & Pursuing Later Treatment Options II (PLATO II) project team 2012, 'Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe', J A I D S, bind 59, nr. 3, s. 294-9. https://doi.org/10.1097/qai.0b013e31823fe66b

@article{8ccbb5c2e0134bc49a01903f045e289d,

title = "Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe",

abstract = "Background: Despite the increasing success of antiretroviral therapy (ART), virologic failure of the 3 original classes [tripleclass virologic failure, (TCVF)] still develops in a small minority of patients who started therapy in the triple combination ART era. Trends in the incidence and prevalence of TCVF over calendar time have not been fully characterised in recent years. Methods: Calendar time trends in the incidence and prevalence of TCVF from 2000 to 2009 were assessed in patients who started ART from January 1, 1998, and were followed within the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Results: Of 91,764 patients followed for a median (interquartile range) of 4.1 (2.0-7.1) years, 2722 (3.0%) developed TCVF. The incidence of TCVF increased from 3.9 per 1000 person-years of follow- up [95% confidence interval (CI): 3.7 to 4.1] in 2000 to 8.8 per 1000 person-years of follow-up (95% CI: 8.5 to 9.0) in 2005, but then declined to 5.8 per 1000 person-years of follow-up (95% CI: 5.6 to 6.1) by 2009. The prevalence of TCVF was 0.3% (95% CI: 0.27% to 0.42%) at December 31, 2000, and then increased to 2.4% (95% CI: 2.24% to 2.50%) by the end of 2005. However, since 2005, TCVF prevalence seems to have stabilized and has remained below 3%. Conclusions: The prevalence of TCVF in people who started ART after 1998 has stabilized since around 2005, which most likely results from the decline in incidence of TCVF from this date. The introduction of improved regimens and better overall HIV care is likely to have contributed to these trends. Despite this progress, calendar trends should continue to be monitored in the long term.",

author = "Fumiyo Nakagawa and Rebecca Lodwick and Dominique Costagliola and {van Sighem}, Ard and Carlo Torti and Daniel Podzamczer and Amanda Mocroft and Bruno Ledergerber and Maria Dorrucci and Alessandra Cozzi-Lepri and Klaus Jansen and Bernard Masquelier and Federico Garc{\'i}a and {De Wit}, Stephane and Christoph Stephan and Niels Obel and Gerd F{\"a}tkenhaeuer and Antonella Castagna and Helen Sambatakou and Cristina Mussini and Jade Ghosn and Robert Zangerle and Xavier Duval and Laurence Meyer and Santiago Perez-Hoyos and {Fabre Colin}, C{\'e}line and Jesper Kjaer and Genevieve Chene and Jesper Grarup and Andrew Phillips and Niels Obel",

year = "2012",

month = mar,

day = "1",

doi = "10.1097/qai.0b013e31823fe66b",

language = "English",

volume = "59",

pages = "294--9",

journal = "J A I D S",

issn = "1525-4135",

publisher = "Lippincott Williams & Wilkins",

number = "3",

}

TY - JOUR

T1 - Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

AU - Nakagawa, Fumiyo

AU - Lodwick, Rebecca

AU - Costagliola, Dominique

AU - van Sighem, Ard

AU - Torti, Carlo

AU - Podzamczer, Daniel

AU - Mocroft, Amanda

AU - Ledergerber, Bruno

AU - Dorrucci, Maria

AU - Cozzi-Lepri, Alessandra

AU - Jansen, Klaus

AU - Masquelier, Bernard

AU - García, Federico

AU - De Wit, Stephane

AU - Stephan, Christoph

AU - Obel, Niels

AU - Fätkenhaeuer, Gerd

AU - Castagna, Antonella

AU - Sambatakou, Helen

AU - Mussini, Cristina

AU - Ghosn, Jade

AU - Zangerle, Robert

AU - Duval, Xavier

AU - Meyer, Laurence

AU - Perez-Hoyos, Santiago

AU - Fabre Colin, Céline

AU - Kjaer, Jesper

AU - Chene, Genevieve

AU - Grarup, Jesper

AU - Phillips, Andrew

AU - Pursuing Later Treatment Options II (PLATO II) project team

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Background: Despite the increasing success of antiretroviral therapy (ART), virologic failure of the 3 original classes [tripleclass virologic failure, (TCVF)] still develops in a small minority of patients who started therapy in the triple combination ART era. Trends in the incidence and prevalence of TCVF over calendar time have not been fully characterised in recent years. Methods: Calendar time trends in the incidence and prevalence of TCVF from 2000 to 2009 were assessed in patients who started ART from January 1, 1998, and were followed within the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Results: Of 91,764 patients followed for a median (interquartile range) of 4.1 (2.0-7.1) years, 2722 (3.0%) developed TCVF. The incidence of TCVF increased from 3.9 per 1000 person-years of follow- up [95% confidence interval (CI): 3.7 to 4.1] in 2000 to 8.8 per 1000 person-years of follow-up (95% CI: 8.5 to 9.0) in 2005, but then declined to 5.8 per 1000 person-years of follow-up (95% CI: 5.6 to 6.1) by 2009. The prevalence of TCVF was 0.3% (95% CI: 0.27% to 0.42%) at December 31, 2000, and then increased to 2.4% (95% CI: 2.24% to 2.50%) by the end of 2005. However, since 2005, TCVF prevalence seems to have stabilized and has remained below 3%. Conclusions: The prevalence of TCVF in people who started ART after 1998 has stabilized since around 2005, which most likely results from the decline in incidence of TCVF from this date. The introduction of improved regimens and better overall HIV care is likely to have contributed to these trends. Despite this progress, calendar trends should continue to be monitored in the long term.

AB - Background: Despite the increasing success of antiretroviral therapy (ART), virologic failure of the 3 original classes [tripleclass virologic failure, (TCVF)] still develops in a small minority of patients who started therapy in the triple combination ART era. Trends in the incidence and prevalence of TCVF over calendar time have not been fully characterised in recent years. Methods: Calendar time trends in the incidence and prevalence of TCVF from 2000 to 2009 were assessed in patients who started ART from January 1, 1998, and were followed within the Collaboration of Observational HIV Epidemiological Research Europe (COHERE). Results: Of 91,764 patients followed for a median (interquartile range) of 4.1 (2.0-7.1) years, 2722 (3.0%) developed TCVF. The incidence of TCVF increased from 3.9 per 1000 person-years of follow- up [95% confidence interval (CI): 3.7 to 4.1] in 2000 to 8.8 per 1000 person-years of follow-up (95% CI: 8.5 to 9.0) in 2005, but then declined to 5.8 per 1000 person-years of follow-up (95% CI: 5.6 to 6.1) by 2009. The prevalence of TCVF was 0.3% (95% CI: 0.27% to 0.42%) at December 31, 2000, and then increased to 2.4% (95% CI: 2.24% to 2.50%) by the end of 2005. However, since 2005, TCVF prevalence seems to have stabilized and has remained below 3%. Conclusions: The prevalence of TCVF in people who started ART after 1998 has stabilized since around 2005, which most likely results from the decline in incidence of TCVF from this date. The introduction of improved regimens and better overall HIV care is likely to have contributed to these trends. Despite this progress, calendar trends should continue to be monitored in the long term.

UR - http://www.ncbi.nlm.nih.gov/pubmed/22083070

U2 - 10.1097/qai.0b013e31823fe66b

DO - 10.1097/qai.0b013e31823fe66b

M3 - Journal article

C2 - 22083070

SN - 1525-4135

VL - 59

SP - 294

EP - 299

JO - J A I D S

JF - J A I D S

IS - 3

ER -

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe

Abstract

FN’s Verdensmål

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater